Stock listing
BHVN Stock Price, News, Filings & Events — Biohaven Ltd.
Selected listing: BHVN · NYSE · USD · US
This page tracks Biohaven Ltd.'s BHVN:NYSE listing on NYSE in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following BHVN:NYSE. BHVN:NYSE is the stock-level entry point for investors researching Biohaven Ltd., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Biohaven Ltd. is a public company traded under the ticker BHVN in the American market. The company has a market capitalization of approximately $2.34 billion. Biohaven focuses on developing innovative therapies for neurological diseases, aiming to improve patient outcomes.
- Ticker
- BHVN:NYSE
- Asset type
- Stock
- Market cap
- $2.03B
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- NYSE
- Currency
- USD
Biohaven Ltd. BHVN:NYSE stock context
This page tracks Biohaven Ltd.'s BHVN:NYSE listing on NYSE in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following BHVN:NYSE. BHVN:NYSE is the stock-level entry point for investors researching Biohaven Ltd., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Biohaven Ltd. is a public company traded under the ticker BHVN in the American market. The company has a market capitalization of approximately $2.34 billion. Biohaven focuses on developing innovative therapies for neurological diseases, aiming to improve patient outcomes.
Latest news from Biohaven Ltd.
Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead ...
August 27, 2026
Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx...
July 20, 2026
Biohaven Announces Scientific Leadership Transitions
July 9, 2026
Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator
June 30, 2026
Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivo...
June 29, 2026
Biohaven Ltd. earnings calls
Biohaven Ltd. (BHVN) Q4 2021 Earnings Call
February 25, 2022 · Replay with transcript and chapters
Biohaven Ltd. (BHVN) Q3 2021 Earnings Call
November 9, 2021 · Replay with transcript and chapters
Biohaven Ltd. (BHVN) Q2 2021 Earnings Call
August 9, 2021 · Replay with transcript and chapters
Biohaven Ltd. (BHVN) Q1 2021 Earnings Call
May 10, 2021 · Replay with transcript and chapters
Biohaven Ltd. (BHVN) Q4 2020 Earnings Call
March 1, 2021 · Replay with transcript and chapters
Research Biohaven Ltd.
Biohaven Ltd. investor report
Review AI stock analysis and investor report context for BHVN:NYSE.
Biohaven Ltd. company profile
View the public company page for Biohaven Ltd. on 6ix.
Biohaven Ltd. news
Read company news and market updates connected to Biohaven Ltd..
Biohaven Ltd. investor events
Find investor webinars, events, and replay context for Biohaven Ltd..
Alternate listings
ZH6:TRADEGATE
DE · EUR
Alternate listing for Biohaven Ltd.; the primary context on this page is BHVN:NYSE.
BHVN34:BMFBOVESPA
BR · BRL
Alternate listing for Biohaven Ltd.; the primary context on this page is BHVN:NYSE.
BHVN:BOATS
US · USD
Alternate listing for Biohaven Ltd.; the primary context on this page is BHVN:NYSE.